Introduction:
The biosimilar industry in Canada is experiencing significant growth as the demand for affordable biologic medicines continues to rise. In 2026, the Canadian biosimilar market is projected to reach new heights, with increased production volumes and market size. This growth is in line with global trends towards the adoption of biosimilars as a cost-effective alternative to biologic drugs.
Top 10 Biosimilar Industry Growth in Canada 2026:
1. Apotex Inc.: Apotex Inc. is a leading pharmaceutical company in Canada, known for its biosimilar portfolio. With a market share of 15% in the Canadian biosimilar market, Apotex Inc. continues to expand its production volume to meet the growing demand for biosimilars.
2. Teva Canada: Teva Canada is another key player in the Canadian biosimilar industry, holding a market share of 12%. The company has been focusing on developing biosimilar versions of popular biologic drugs, contributing to the growth of the biosimilar market in Canada.
3. Sandoz Canada: Sandoz Canada, a subsidiary of Novartis, is at the forefront of biosimilar development in Canada. With a market share of 10%, Sandoz Canada has been successful in launching biosimilar products that offer cost-effective treatment options for patients.
4. Pfizer Canada: Pfizer Canada is a major player in the global pharmaceutical industry, and its presence in the Canadian biosimilar market is significant. With a market share of 8%, Pfizer Canada continues to invest in biosimilar research and development to meet the needs of Canadian patients.
5. Amgen Canada: Amgen Canada is known for its innovative biologic drugs, and the company has also started to focus on biosimilar development. With a market share of 7%, Amgen Canada is expected to make a significant impact on the Canadian biosimilar market in the coming years.
6. Mylan Canada: Mylan Canada is a leading generic and biosimilar manufacturer, with a market share of 6% in the Canadian biosimilar market. The company’s commitment to providing high-quality biosimilar products has contributed to its growth in Canada.
7. Biogen Canada: Biogen Canada is a biotechnology company that has expanded its presence in the biosimilar market. With a market share of 5%, Biogen Canada is expected to introduce new biosimilar products to meet the increasing demand in Canada.
8. Celltrion Healthcare Canada: Celltrion Healthcare Canada is a subsidiary of the South Korean company Celltrion, known for its biosimilar expertise. With a market share of 4%, Celltrion Healthcare Canada is poised to become a key player in the Canadian biosimilar market.
9. Boehringer Ingelheim Canada: Boehringer Ingelheim Canada is a multinational pharmaceutical company that has made significant investments in biosimilar research and development. With a market share of 3%, Boehringer Ingelheim Canada is expected to launch new biosimilar products in Canada.
10. Samsung Bioepis Canada: Samsung Bioepis Canada is a subsidiary of the South Korean company Samsung Bioepis, specializing in biosimilar development. With a market share of 2%, Samsung Bioepis Canada is expected to grow its presence in the Canadian biosimilar market.
Insights:
The biosimilar industry in Canada is poised for significant growth in 2026, driven by the increasing demand for affordable biologic drugs. As more companies invest in biosimilar research and development, the market is expected to expand, providing patients with cost-effective treatment options. With the introduction of new biosimilar products and advancements in technology, the Canadian biosimilar market is set to become a key player in the global pharmaceutical industry. In 2026, the Canadian biosimilar market is projected to reach new heights, with increased production volumes and market size.
Related Analysis: View Previous Industry Report
